Press Releases

Alys Pharmaceuticals, Inc. an immune-dermatology focused company, today announces that the U.S. Food and Drug Administration (FDA) and Health Canada have cleared the Investigational New Drug (IND) / Clinical Trial Application (CTA) for the study of ALY-101 in patients suffering from Alopecia Areata (AA). The Phase 2a trial will evaluate the safety and efficacy of ALY-101, an intradermal injectable JAK1 siRNA-lipid conjugate, at five sites across the United States and Canada. AA is a

NRx Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc. a medical and technology driven company and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. announced today that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals will be presenting a Company update at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on February 11th-12th. The presentatio

Vanda Pharmaceuticals Inc. today announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully completed two registration-enabling global Phase 3 trials, GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of imsidolimab in patients with Generalized Pustular Psoriasis (GPP). GPP is a rare skin disorder often caused by mutations in the IL36RN gene that codes for a regulatory protein that

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. ("Kadimastem") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing "off-the-shelf" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure for diabetes, are pleased t

Renalys Pharma, Inc. announced today that it has completed patient enrollment for its registrational Phase III clinical trial of sparsentan for the treatment of IgA nephropathy in Japan. In April 2024 Renalys submitted an Investigational New Drug (IND) Application for sparsentan to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. The registrational Phase III study is a multicenter, open-label, single arm study in Japanese patients with IgA nephropathy, and is planned

HealthTech BioActives (HTBA), a global leader in the manufacture of citrus flavonoids and active forms of vitamin B12, has announced the completion of a €25 million investment project to modernize its research, development and manufacturing center in Murcia, Spain. The initiative included the construction of a new state-of-the-art production plant, which was officially inaugurated on Tuesday 28 January, making HTBA the only company in Europe capable of producing all active forms of vitam

AptarGroup, Inc. a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that the Board declared a quarterly cash dividend of $0.45 per share. As previously announced, Aptar will hold a conference call on Friday, February 7, 2025 at 8:00 a.m. Central Time to discuss the Company’s fourth quarter and year-end results for 2024. The call will last approximately one hour. Interested parties are invited to listen to a live webcast

CPC, part of Dover and a leading manufacturer of connection technologies used in biopharmaceutical processing, today announced the launch of its new MicroCNX® Nano Series aseptic connectors, designed to significantly simplify cell and gene therapy (CGT) closed sterile processing. "Cell and gene therapy is advancing quickly, but the industry relies on older, cumbersome techniques like biosafety cabinets or tube welding for sterile processing," said Troy Ostreng, Senior

NLS Pharmaceutics Ltd. a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous system disorders, is proud to announce the launch of a preclinical program evaluating Mazindol ER (Extended-Release) as a novel treatment for fentanyl dependence. Fentanyl dependence is a major global health crisis and was recently declared a national public health emergency by the new Trump administration. In 2023, the CDC reported 105,007 drug overdo

Lyfegen, a global innovator in drug market access, pricing, and rebate management, has announced a transformative collaboration with EVERSANA®, a leading provider of global commercial services to the life sciences industry, to revolutionize drug pricing and access through artificial intelligence-driven insights. By combining data and information from the global pricing and market access platform, NAVLIN by EVERSANA®, with Lyfegen's Public Drug Agreement Library, the two